Results 71 to 80 of about 1,936,563 (245)
In this paper we describe a case of a 65-year old man with a lymphoid blastic crisis of a chronic granulocytic leukemia occurring seven years after a palatine tonsillar non-Hodgkin's lymphoma treated with chemotherapy and radiation therapy.
L Mele +7 more
doaj
Chronic Myeloid Leukemia: From the Classical Presentation Towards Rare Instances of Associated Blast Crises - Case Comparison and Literature Review [PDF]
Chronic myeloid leukemia/CML accounts up to 20% of leukemia cases in the adult population. Even though the TKI (tyrosine kinase inhibitors) era has brought major improvements regarding evolution and prognosis, there are still certain particularities ...
Alexandra MARCOCI +5 more
doaj +1 more source
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms
Damien Blez +10 more
doaj +1 more source
Abstract Accurate immunophenotypic evaluation of natural killer (NK)‐cell neoplasms is challenging because NK‐cells lack somatically rearranged antigen receptors, are comprised of phenotypically distinct subsets, and exhibit tissue‐specific subset distribution. We developed a flow cytometry (FC) panel for NK‐cell immunophenotypic analysis and clonality
Valerie Woodings +7 more
wiley +1 more source
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
-
Marta Muzio +2 more
doaj +3 more sources
Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core +1 more source
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K. +18 more
core +1 more source
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Background Despite advances in understanding the principles of leukemia biology and therapeutic achievements, older patients with leukemia continue to face serious challenges.
Jing Wei, Qijian Feng, Ziyuan Lu
doaj +1 more source
Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio +71 more
core +2 more sources

